Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has shared an update.
TempraMed Technologies Ltd., a medical-technology company focused on temperature-controlled medication storage, has secured a Chinese patent for its upcoming VIVI Box multi-medication storage platform, strengthening protection of its proprietary thermal-insulation and smart-monitoring technology in one of the world’s largest healthcare and consumer markets. The patent, granted by China’s CNIPA and effective through October 2039, underpins TempraMed’s strategy to move beyond single-injection devices into scalable, multi-dose storage systems.
The VIVI Box, expected to launch at the end of 2026, is designed to provide continuous temperature protection during power interruptions, portable all-day cold storage, and cloud-connected monitoring to support adherence and remote oversight. This new Chinese patent, alongside a similar grant in South Korea and recent distribution agreements, bolsters TempraMed’s global commercialization plans and supports its ambitions to become a leading player in temperature-regulated medication protection and management, including potential collaborations with premium refrigeration manufacturers across Asia.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global medical device company specializing in innovative, temperature-controlled storage solutions for life-saving, temperature-sensitive medications. Its patented, FDA-registered thermal insulation devices, including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, operate without batteries or external power and are marketed across North America, Europe, and Asia.
The company focuses on enabling patients and healthcare providers to manage cold-chain dependent therapies reliably at home and on the move, targeting the growing market for connected, adherence-supporting medication management tools. TempraMed aims to expand its portfolio and global reach as demand rises for safer storage of biologics and other sensitive drugs.
Average Trading Volume: 59,002
Technical Sentiment Signal: Strong Sell
Learn more about VIVI stock on TipRanks’ Stock Analysis page.